정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2102 | Completed | Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions | Bioequivalence | Drug: Test: Favipiravir 200 mg (LOQULAR) Drug: Reference: Favipiravir 200 mg (Avigan) |
Phase 1 | World Medicine ILAC SAN. ve TIC. A.S., Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti | INDUSTRY | 30 | Male | 20 Years ~ 40 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey |
2101 | Completed | Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions | Bioequivalence | Drug: FAVIR 200 MG FT Drug: AVIGAN 200 mg FT |
Phase 1 | Kocak Farma, Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti | INDUSTRY | 30 | Male | 18 Years ~ 40 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey |
2100 | Completed | Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions | Bioequivalence | Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet |
Phase 1 | World Medicine ILAC SAN. ve TIC. A.S., Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti | INDUSTRY | 30 | Male | 20 Years ~ 40 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey |
2099 | Completed | BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 | Nasal Congestion | Drug: BNO 1030 Other: Standard care |
Phase 4 | Ivano-Frankivsk National Medical University | OTHER | 133 | All | 18 Years ~ 70 Years | Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine |
2098 | Active, not recruiting | BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers | Immunization; Infection | Biological: two doses of BNT162b2 vaccine Biological: one dose of BNT162b2 vaccine |
Phase 2 | ANRS, Emerging Infectious Diseases, Institut National de la Sante Et de la Recherche Medicale, France | OTHER_GOV | 267 | All | 18 Years | CIC1412, CHRU Brest, Brest, France Centre de Recherche Clinique, CHU Cote de Nacre, Caen, France CIC 1405 , CHU Clermont-Ferrand, Clermont-Ferrand, France CIC1430, Hopital Henri Mondor, Creteil, France CIC1413 , Hotel Dieu - CHU Nantes, Nantes, France Service des maladies infectieuses, CHU de Caremeau, Nimes, France CIC1417, hopital Cochin, Paris, France CIC 1427, Hopital Saint-Louis, Paris, France URCI, Hopital Lyon Sud, Pierre-Benite, France CIC1434, Nouvel Hopital Civil - Hopitaux Universitaires de Strasbourg, Strasbourg, France CIC1415, CHRU Tours Hopital Bretonneau, Tours, France |
2097 | Not yet recruiting | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) | Coronavirus Disease 2019 (COVID-19) | Biological: BM-MSCs Biological: Placebo |
Phase 2 | Guangzhou Institute of Respiratory Disease, Guangzhou Eighth People's Hospital, Tongji Hospital, Guangzhou Cellgenes Biotechnology Co.,Ltd | OTHER | 20 | All | 18 Years ~ 75 Years | Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China |
2096 | Not yet recruiting | Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response | Immunosuppression | Biological: The Pfizer mRNA-based BNT162b2 vaccine | Phase 4 | dafna yahav | OTHER | 504 | All | 18 Years |